IRIS UniCatt

Guidi, Luisa
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.831
EU - Europa 2.788
AS - Asia 2.388
SA - Sud America 472
Continente sconosciuto - Info sul continente non disponibili 100
AF - Africa 74
AN - Antartide 1
Totale 9.654
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.728
SG - Singapore 1.105
DE - Germania 1.015
CN - Cina 590
SE - Svezia 461
BR - Brasile 376
IT - Italia 253
FR - Francia 247
UA - Ucraina 242
VN - Vietnam 169
GB - Regno Unito 148
IE - Irlanda 131
IN - India 121
ID - Indonesia 86
FI - Finlandia 68
JP - Giappone 50
TR - Turchia 49
CA - Canada 48
PL - Polonia 48
RU - Federazione Russa 48
BD - Bangladesh 47
AR - Argentina 35
HK - Hong Kong 35
BE - Belgio 25
MX - Messico 23
ZA - Sudafrica 22
NL - Olanda 20
IQ - Iraq 19
ES - Italia 18
SA - Arabia Saudita 18
VE - Venezuela 17
AT - Austria 15
CO - Colombia 15
EC - Ecuador 15
IR - Iran 13
PK - Pakistan 11
MA - Marocco 10
PH - Filippine 10
CI - Costa d'Avorio 9
NP - Nepal 9
JM - Giamaica 8
KR - Corea 8
CZ - Repubblica Ceca 7
TN - Tunisia 7
KE - Kenya 6
CR - Costa Rica 5
HU - Ungheria 5
JO - Giordania 5
PT - Portogallo 5
UY - Uruguay 5
UZ - Uzbekistan 5
AE - Emirati Arabi Uniti 4
BG - Bulgaria 4
CH - Svizzera 4
DZ - Algeria 4
GR - Grecia 4
IL - Israele 4
LT - Lituania 4
AL - Albania 3
AO - Angola 3
CL - Cile 3
EG - Egitto 3
ET - Etiopia 3
HN - Honduras 3
LV - Lettonia 3
OM - Oman 3
TH - Thailandia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AM - Armenia 2
AZ - Azerbaigian 2
BB - Barbados 2
BH - Bahrain 2
BN - Brunei Darussalam 2
BZ - Belize 2
CG - Congo 2
DK - Danimarca 2
DO - Repubblica Dominicana 2
GT - Guatemala 2
HR - Croazia 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MY - Malesia 2
PE - Perù 2
PR - Porto Rico 2
PY - Paraguay 2
RO - Romania 2
TW - Taiwan 2
AQ - Antartide 1
BO - Bolivia 1
BS - Bahamas 1
BY - Bielorussia 1
CW - ???statistics.table.value.countryCode.CW??? 1
CY - Cipro 1
EU - Europa 1
GA - Gabon 1
GP - Guadalupe 1
GY - Guiana 1
HT - Haiti 1
KH - Cambogia 1
Totale 9.544
Salva come PNG Salva come JPEG
Città #
Singapore 622
Chandler 554
Ashburn 373
San Jose 320
Jacksonville 168
Beijing 142
Dublin 126
New York 123
San Mateo 122
Dearborn 107
Ann Arbor 101
Los Angeles 86
Jakarta 75
Nanjing 71
Lauterbourg 69
Wilmington 65
Munich 64
Cattolica 59
Nürnberg 59
Boston 55
Milan 48
Tokyo 45
Ho Chi Minh City 41
Hefei 39
Houston 39
Hanoi 38
Bremen 34
Princeton 34
Frankfurt am Main 33
Lawrence 33
Moscow 30
São Paulo 30
Hong Kong 28
Izmir 28
Dallas 27
Seattle 25
Warsaw 25
Marseille 24
Brussels 23
Buffalo 23
Lancaster 22
Rome 22
Fairfield 21
Kraków 21
Santa Clara 21
Nanchang 20
Boardman 19
The Dalles 19
Woodbridge 19
Redwood City 18
Guangzhou 17
Shenyang 17
Changsha 16
Hangzhou 16
Shanghai 16
Augusta 15
Chicago 14
Helsinki 14
London 14
Da Nang 13
Leawood 13
Atlanta 12
Detroit 12
Mountain View 12
Rio de Janeiro 12
Tianjin 12
Toronto 12
Belo Horizonte 11
Brasília 11
Brooklyn 11
Hebei 11
Jiaxing 11
Johannesburg 11
Nuremberg 11
Paris 11
Philadelphia 11
Stockholm 11
Baghdad 10
Hyderabad 10
Kunming 10
Norwalk 10
Pune 10
San Francisco 10
Abidjan 9
Redmond 9
Zhengzhou 9
Ardabil 8
Costa Mesa 8
Düsseldorf 8
Phoenix 8
Turku 8
Vienna 8
Amsterdam 7
Andover 7
Ankara 7
Cagliari 7
Denver 7
Haiphong 7
Jeddah 7
Kent 7
Totale 4.748
Salva come PNG Salva come JPEG
Nome #
A) Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease. 373
Paradoxical psoriasis in a large cohort of patients with inflammatory bowel disease receiving treatment with anti-TNF alpha: 5-year follow-up study 235
FOXP3⁺ T regulatory cell modifications in inflammatory bowel disease patients treated with anti-TNFα agents 219
Early atherosclerosis in patients with inflammatory bowel disease. 218
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission. 214
Comparison of Quantiferon-TB Gold versus tuberculin skin test for tuberculosis screening in inflammatory bowel disease patients. 201
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 201
Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy with immunosuppressants. 199
-Increased carotid intima-media thickness in patients with inflammatory bowel disease 194
Development of psoriasis scalp with alopecia during treatment of Crohn's disease with infliximab and rapid response to both diseases to ustekinumab 189
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 185
Ileal Crohn's disease: CEUS determination of activity 184
Prevalence and natural history of hepatitis B and C infections in a large population of IBD patients treated with anti-tumor necrosis factor-α agents 180
Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis. 176
Sonography of the small bowel after oral administration of fluid: an assessment of the diagnostic value of the technique 171
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 171
Comparison of performances of infliximab biosimilars CT-P13 versus SB2 in the treatment of inflammatory bowel diseases: a real-life multicenter, observational study in Italy 167
Magnesium Absorption in Intestinal Cells: Evidence of Cross-Talk between EGF and TRPM6 and Novel Implications for Cetuximab Therapy 166
Use of infliximab in particular clinical settings: management based on current evidence. 160
Enteroclysis CT and PEG-CT in patients with previous small-bowel surgical resection for Crohn's disease: CT findings and correlation with endoscopy 155
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 155
Dermatological adverse reactions during anti-TNF treatments: Focus on inflammatory bowel disease. 154
Anti-TNF-alpha therapies do not increase early postoperative complications in patients with inflammatory bowel disease. An Italian single-center experience. 152
Therapeutic drug monitoring of anti-TNF-α agents in inflammatory bowel diseases 151
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 147
Faecal calprotectin assay after induction with anti-Tumour Necrosis Factor α agents in inflammatory bowel disease: Prediction of clinical response and mucosal healing at one year. 147
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 145
Management of perianal fistulas in Crohn's disease: an up-to-date review 137
Benefit–risk assessment of golimumab in the treatment of refractory ulcerative colitis 137
Transition of inflammatory bowel disease patients from pediatric to adult care: an observational study on a joint-visits approach 135
Impact of COVID-19 pandemic on the daily management of biotechnological therapy in inflammatory bowel disease patients: Reorganisational response in a high-volume Italian inflammatory bowel disease centre 135
What is the best way to manage screening for infections and vaccination of inflammatory bowel disease patients? 134
Clinical management of rheumatologic conditions co-occurring with inflammatory bowel diseases 134
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 130
Paradoxical arthritis occurring during anti-TNF in patients with Inflammatory Bowel Disease: histological and immunological features of a complex synovitis. 128
A case of hereditary hemorrhagic telangiectasia associated with Crohn's disease successfully treated with infliximab. 124
Therapeutic drug monitoring is more cost-effective than a clinically-based approach in the management of loss of response to infliximab in inflammatory bowel disease: an observational multi-centre study. 122
Changes in admissions, and hospitalization outcomes of IBD patients in an Italian tertiary referral center over a 13-year period 118
AID in aging and autoimmune diseases 114
Dual Targeted Therapy: a possible option for the management of refractory Inflammatory Bowel Disease 113
Mucosal healing in ulcerative colitis: surveillance or colectomy? 112
Predictors and early markers of response to biological therapies in inflammatory bowel diseases 110
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 108
Ileal Crohn disease: mural microvascularity quantified with contrast-enhanced US correlates with disease activity 107
TRPM7 Is Overexpressed in Human IBD-Related and Sporadic Colorectal Cancer and Correlates with Tumor Grade 107
Neuropeptide Y plasma levels and immunological changes during academic stress 106
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 106
Linking estrogen receptor β expression with inflammatory bowel disease activity 106
[Soluble factors with immunosuppressive activity in human neoplasms] 102
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 100
The Italian registry of therapeutic apheresis: Granulocyte-monocyte apheresis in the treatment of inflammatory bowel disease. A multicentric study 99
Anti-TNF alpha therapy in the management of extraintestinal manifestation of inflammatory bowel disease. 98
Acute cytomegalovirus infection as a possible trigger for pulmonary thromboembolism in a patient with steroid-refractory ulcerative colitis. 94
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 94
Adalimumab in active ulcerative colitis: a "real-life" observational study 93
Harmful effects and potential benefits of anti-tumor necrosis factor (TNF)-α on the liver 93
Novel trends with biologics in inflammatory bowel disease: sequential and combined approaches 93
Fever of unknown origin due to Coxiella burnetii, an unexpected guest in primary sclerosing cholangitis 92
Management of difficult-to-treat patients with ulcerative colitis: focus on adalimumab 91
The PROSit cohort of infliximab biosimilar in IBD: A prolonged follow-up on the effectiveness and safety across Italy 91
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study. 90
Therapeutic drug monitoring with vedolizumab in inflammatory bowel disease 89
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 89
Sustained clinical efficacy and mucosal healing of thiopurine maintenance treatment in ulcerative colitis: A real-life study 85
Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: Early and late outcome and predictors of colectomy 84
Predictors of clinical response in patients with ulcerative colitis treated with granulocyte-monocyte apheresis: analysis of the apheresis registry data 81
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar. 80
Watery stools and metabolic acidosis 78
Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. 77
Combined therapy with infliximab and seton drainage for perianal fistulizing Crohn's disease with anal endosonographic monitoring: A single-centre experience 73
Serum levels of metalloproteinases and their inhibitors in nonalcoholic steatohepatitis 62
Small bowel diseases 47
Small bowel diseases 47
Totale 9.654
Salva come PNG Salva come JPEG
Categoria #
all - tutte 40.981
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 40.981
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022546 0 0 9 107 16 14 8 116 19 27 106 124
2022/20231.376 184 193 96 233 109 159 54 115 172 10 33 18
2023/2024639 30 185 18 46 17 112 25 38 10 22 62 74
2024/20251.116 23 42 117 18 122 46 37 65 156 123 199 168
2025/20262.947 494 70 154 337 510 127 562 131 173 225 101 63
2026/2027426 108 181 137 0 0 0 0 0 0 0 0 0
Totale 9.654